



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

19 April 2023

Results of Non-renounceable Entitlement Offer

MELBOURNE – Imagion Biosystems (**ASX:IBX, Imagion or the Company**) refers to its announcement titled 'Non-renounceable Entitlement Offer' dated 7 March 2023 in relation to the pro rata non-renounceable entitlement offer to existing eligible shareholders to raise up to \$2.4 million through the offer of one (1) new fully paid ordinary shares in the Company for every eight (8) shares held by eligible shareholders registered at 10 March 2023 at an issue price of \$0.017 per share (**Offer**).

Capitalised terms used in this announcement but not defined have the meaning given to them in the Offer Document released to ASX on 7 March 2023, unless the context requires otherwise.

The Company today announces the results of the Offer. The Offer to Eligible Shareholders closed on 14 April 2023.

A total of approximately \$412,903, represented by 24,288,420 Shares, has been received from Eligible Shareholders in respect of the Offer. Of this approximately \$243,223 in applications were in relation to their Entitlements with a further approximately \$169,680 in applications for Additional Shares under the Top-Up Facility.

The New Shares are expected to be issued on 21 April 2023 with trading expected to commence on 24 April 2023.

Approximately \$1.97 million, representing 115,878,572 shares remain as a Shortfall. The Company has until 14 July 2023 to place the Shortfall at the Board's discretion (but at a price no less than the Issue Price under the Offer). The Company will provide a further update in relation to Shortfall placements as and when required.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited

U.S. Media Contact:

Casie Ost

Casie.ost@imagionbio.com

+1-619-693-4428

Australian Media & Investor Relations:

Hannah Howlett, WE Communications

We-AUImagionBiosystems@we-worldwide.com

+61 (0) 450648064

Imagion Biosystems Limited

ACN 616 305 027

Level 25, 525 Collins Street, Melbourne VIC 3000

www.imagionbiosystems.com